Analyst Reco. Cytokinetics, Incorporated

Equities

CYTK

US23282W6057

Market Closed - Nasdaq Other stock markets 01:30:00 01/05/2024 am IST			5-day change	1st Jan Change
61.32 ^USD	-1.94%		-6.48%	-26.55%

26/04	Cytokinetics Appoints Sung Lee as CFO	MT
26/04	Cytokinetics, Incorporated Appoints Sung H. Lee as Executive Vice President, Effective as of May 8, 2024	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cytokinetics Insider Sold Shares Worth $2,422,918, According to a Recent SEC Filing	10/04	MT
Mizuho Securities Adjusts Price Target on Cytokinetics to $99 From $103, Maintains Buy Rating	06/03	MT
UBS Downgrades Cytokinetics to Neutral From Buy, Adjusts Price Target to $92 From $61	24/01	MT
Mizuho Securities Boosts Price Target on Cytokinetics to $103 From $80, Keeps Buy Rating	19/01	MT
B. Riley Raises Cytokinetics' PT to $122 From $66, Keeps Buy Rating; Notes Heightened Conviction in Aficamten Taking Dominant Market Share Cardiac Myosin Inhibitor Market	08/01	MT
Truist Securities Raises Cytokinetics' Price Target to $86 From $60, Buy Rating Kept	28/12	MT
Needham Raises Cytokinetics' Price Target to $108 From $60, Keeps Buy Rating	28/12	MT
HC Wainwright Raises Cytokinetics Price Target to $94 From $58, Maintains Buy Rating	27/12	MT
Cantor Fitzgerald Raises Cytokinetics Price Target to $101 From $65, Maintains Overweight Rating	27/12	MT
Goldman Sachs Starts Coverage on Cytokinetics with Buy Rating, $50 Price Target	09/11	MT
B. Riley Initiates Cytokinetics With Buy Rating, $66 PT; Says Aficamten's Differentiation Remains Underappreciated	07/11	MT
UBS Trims Cytokinetics' Price Target to $61 From $62, Keeps Buy Rating	03/11	MT
HC Wainwright Adjusts Cytokinetics Price Target to $58 From $49, Maintains Buy Rating	20/23/20	MT
Cantor Fitzgerald Adjusts Cytokinetics' Price Target to $65 From $59, Keeps Overweight Rating	09/23/09	MT
SVB Initiates Cytokinetics at Outperform	15/23/15	MT
JPMorgan Raises Cytokinetics' Price Target to $54 From $52, Maintains Overweight Rating	22/23/22	MT
UBS Adjusts Cytokinetics Price Target to $62 From $61, Maintains Buy Rating	05/23/05	MT
UBS Adjusts Cytokinetics Price Target to $61 From $67, Maintains Buy Rating	03/23/03	MT
Cantor Fitzgerald Adjusts Price Target on Cytokinetics to $59 From $61, Maintains Overweight Rating	03/23/03	MT
JPMorgan Chase Adjusts Price Target on Cytokinetics to $52 From $55, Maintains Overweight Rating	20/23/20	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Cytokinetics, Incorporated

Equities

CYTK

US23282W6057

Analyst Reco.

Filters